Don Deyo: Breakthrough Therapy for Post-Stroke Upper Limb Impairment Now Published
Don Deyo, Executive Chair at Reach Neuro, Inc., shared on LinkedIn about a recent article by Roberto M. de Freitas et al, published in Nature Medicine, adding:
”I am excited to share that the clinical research underlying Reach Neuro‘s breakthrough therapy for post-stroke upper limb impairment has been published in Nature Medicine.
For stroke survivors, the loss of arm and hand function can have a profound impact on independence and quality of life.
This study demonstrates that targeted spinal cord stimulation can significantly improve arm strength, mobility, and dexterity, even years after a stroke.
This publication represents an important milestone in the journey to bring a transformative therapy to the millions of people living with chronic stroke-related disability.
It is a testament to the vision, dedication, and scientific excellence of the researchers, clinicians, engineers, and study participants who made this work possible.
As Executive Chairman of Reach Neuro, I am honored to work alongside such an exceptional team as we advance this technology toward broader clinical application.
My congratulations and gratitude go to Dr. Marco Capogrosso, Dr. Peter Gerszten, Dr. Douglas Weber, Dr. Elvira Pirondini, their collaborators, and the study participants whose commitment made this achievement possible.
Read more about the publication and its significance.”
Title: Spinal cord stimulation for upper limb motor function in people with chronic post-stroke hemiparesis: a feasibility trial
Authors: Roberto M. de Freitas, Shovan Bhatia, Erynn Sorensen, Nikhil Verma, Erick Carranza, Scott Ensel, Luigi Borda, Amy Boos, Jeff Goldsmith, Lee E. Fisher, Daryl P. Fields, Marc P. Powell, Shane Gordon, Jeffrey Balzer, Robert M. Friedlander, George F. Wittenberg, Peter C. Gerszten, John W. Krakauer, Elvira Pirondini, Douglas J. Weber, Marco Capogrosso
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand
-
Oct 16, 2026, 16:01Obi Light Ogbonnia: The Greatest Reward Is Changing Lives, Not Winning Awards
-
Oct 16, 2026, 15:18Carmine Liberatore: Limited Accuracy of VTE Risk Scores in Multiple Myeloma
-
Oct 16, 2026, 14:55Alex Borstein and the Bleeding Phenotype of Hemophilia A Carriers
-
Oct 16, 2026, 13:59Aya Akmal Amin: Antiphospholipid Syndrome Management and Risk Stratification
-
Oct 16, 2026, 13:10Emanuel Sueldo: CAHT 2026 Celebrates Scientific Progress and Team Achievements
-
Oct 16, 2026, 13:05Maha Othman: Queen’s Health Sciences Advances CAT Risk Models and Pediatric ISTH-BAT Cut-Offs
-
Oct 16, 2026, 13:03Thrombosis Awareness Must Lead to Timely Action – Roche
-
Oct 16, 2026, 12:49Wolfgang Miesbach: 5-Year CBDR Data Confirms Emicizumab Safety and Efficacy in Hemophilia A